Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.280 +0.0% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4% S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.280 +0.0% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4%

Healthcare

Page 42
  1. Mar 26, 2026 · 08:00 · QNTM

    Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

    Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

    01
  2. Mar 26, 2026 · 07:30 · EDT

    Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update

    Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update

    02
  3. Mar 26, 2026 · 07:30 · NPTH

    NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2025 RESULTS

    NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2025 RESULTS

    03
  4. Mar 26, 2026 · 04:16 · NGMD

    Nugen files patent for needle-free injection nozzle

    Nugen files patent for needle-free injection nozzle

    04
  5. Mar 25, 2026 · 18:47 · DHT

    DRI Healthcare closes $250M (U.S.) offering of notes

    DRI Healthcare closes $250M (U.S.) offering of notes

    05
  6. Mar 25, 2026 · 17:15 · NGMD · Routine +

    NuGen Files Needle-Free Nozzle Patent as Stock Tests Multi-Year Lows

    NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology

    06
  7. Mar 25, 2026 · 17:05 · CSCI · Routine +

    COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue

    COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    07
  8. Mar 25, 2026 · 16:22 · GSD

    Devonian Health Faces Liquidity Cliff as Distribution Revenue Dries Up and Biotech Pivot Demands Fresh Capital

    Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026

    08
  9. Mar 25, 2026 · 16:00 · MRVL

    Marvel Biosciences selects Novotech for MB-204 trial

    Marvel Biosciences selects Novotech for MB-204 trial

    09
  10. Mar 25, 2026 · 13:37 · DHT · Routine +

    DRI Healthcare Closes $250M Debt Roll as Leverage Climbs and EBITDA Guidance Slips

    DRI Healthcare Trust Announces Closing of US$250 Million of Senior Secured Notes

    10
  11. Mar 25, 2026 · 12:27 · AIAI · Routine +

    NetraMark’s AI Platform Gains Oncology Validation as Cash Burn Outpaces Revenue Growth

    Netramark, FMP to analyze ROME oncology data

    11
  12. Mar 25, 2026 · 08:20 · LOBE · Routine +

    Lobe Sciences Trims Liabilities and Warrants as Cash Pile Grows, But Clinical Catalysts Remain Unpriced

    Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update

    12
  13. Mar 25, 2026 · 07:31 · CHER · Neutral

    Cheelcare Scales Revenue but Cash Burn Threatens Runway as Stock Fades from Peak

    Cheelcare Announces Third Quarter 2026 Financial Results

    13
  14. Mar 25, 2026 · 07:30 · MRVL · Routine +

    Marvel Biosciences Secures Modest Grant to Bridge Phase I, But $4.3M Debt Overhang Looms Over Clinical Ambitions

    Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

    14
← Newer Older →